Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT03539822 · ClinicalTrials.gov registry record · Phase 1

Cabozantinib Plus Durvalumab With or Without Tremelimumab in Patients With Gastroesophageal Cancer and Other Gastrointestinal Malignancies

A Phase 1 study of Colorectal Cancer and Gastric Cancer, sponsored by Anwaar Saeed.

Recruiting
Registry status
Phase 1
Development phase
117
Enrollment target
2
Study locations

NCT03539822 is a Phase 1 study of Colorectal Cancer and Gastric Cancer that is actively recruiting participants, run by Anwaar Saeed. The registered enrollment target is 117 participants, below the 1,511-participant average among 369 other Colorectal Cancer trials with a reported enrollment target (92% lower). The trial reports 2 study locations across 2 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT03539822, a Phase 1 study of Colorectal Cancer and Gastric Cancer, is actively recruiting participants, sponsored by Anwaar Saeed.

RECRUITING
Registry status
Phase 1
Development phase
117 participants
Enrollment target
2
Study locations

Study Summary

The investigators propose to evaluate the safety of drug combinations in patients with advanced gastroesophageal cancer and other gastrointestinal (GI) malignancies. Finding effective novel therapies for patients with advanced gastric cancer and other GI malignancies is an area of great unmet need. The investigators believe that modulating the tumor microenvironment with biologic agents like cabozantinib will have synergistic effect when combined with checkpoint-based immunotherapeutics like durvalumab in this patient population. This is a phase I/II, open label, multi-cohort trial looking at safety, tolerability and efficacy endpoints.

Conditions Studied

Colorectal Cancer Gastric Cancer Hepatocellular Carcinoma Esophageal Adenocarcinoma

Interventions

  • DRUG Cabozantinib
  • DRUG Durvalumab
  • DRUG Tremelimumab

Study Locations (2)

Kansas

  • University of Kansas Cancer Center - Westwood

Pennsylvania

  • UPMC Hillman Cancer Center - Pittsburgh

Trial Details

FieldValue
Enrollment Target 117 participants
Start Date 2018-10-22
Est. Completion 2029-06-30
Phase Phase 1

Sponsor

Anwaar Saeed

5 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT03539822

The ClinicalTrials.gov registry entry for NCT03539822 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 117 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 1,511-participant average among 369 other Colorectal Cancer trials with a reported enrollment target (92% lower). The listed sponsor is Anwaar Saeed, which has 5 total studies on file at ClinicalTrials.gov.

The record links to 4 conditions, with Colorectal Cancer appearing as the primary indexed condition, and to 3 interventions - of which Cabozantinib is the first listed.

NCT03539822 reports 2 study locations spanning 2 distinct geographic areas - top geographies include Kansas, Pennsylvania.

Frequently Asked Questions

What is clinical trial NCT03539822 about?

NCT03539822 is a clinical study titled "Cabozantinib Plus Durvalumab With or Without Tremelimumab in Patients With Gastroesophageal Cancer and Other Gastrointestinal Malignancies". The investigators propose to evaluate the safety of drug combinations in patients with advanced gastroesophageal cancer and other gastrointestinal (GI) malignancies. Finding effective novel therapies for patients with advanced gastric cancer and other GI malignancies is an area of great unmet need. ...

What is the current status of trial NCT03539822?

This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 117 participants. The study started on 2018-10-22. Estimated completion is 2029-06-30.

What conditions does trial NCT03539822 study?

This clinical trial studies the following conditions: Colorectal Cancer, Gastric Cancer, Hepatocellular Carcinoma, Esophageal Adenocarcinoma.

What interventions are being tested in trial NCT03539822?

The interventions under investigation include: Cabozantinib (DRUG), Durvalumab (DRUG), Tremelimumab (DRUG).

Who is sponsoring clinical trial NCT03539822?

This trial is sponsored by Anwaar Saeed, which has 5 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT03539822 being conducted?

This trial has 2 study locations across Kansas, Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Colorectal Cancer

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Colorectal Cancer

All registered trials for this condition

Gastric Cancer

All registered trials for this condition

Kansas

All trials with a study site in Kansas

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.